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Abstract Skeletal muscle regeneration and hypertrophy
are important adaptive responses to both physical activity
and pathological stimuli. This research was performed to
investigate DNA demethylation action on the late phase of
muscle differentiation and early stage of hypertrophy. The
epigenetic process involved in myogenesis was studied
with the DNA-demethylating agent 5-azacytidine (AZA).
We induced muscle differentiation in C2C12 mouse myo-
blasts in the presence of 5 lM AZA and growth or dif-
ferentiation medium for 48, 72, and 96 h. To study a
potential AZA hypertrophic effect, we stimulated 72 h
differentiated myotubes with AZA for 24 h. Unstimulated
cells were used as control. By western blot and immuno-
fluorescence analysis, we examined AZA action on myo-
genic regulatory factors expression, hypertrophic signaling
pathway and myotube morphology. During differentiation,
protein levels of myogenic markers, Myf6 and Myosin
Heavy Chain (MyHC), were higher in AZA stimulated
cells compared to control. Myostatin and p21 analysis
revealed morphological changes which reflect a tendency
to hypertrophy in myotubes. In AZA stimulated neo
formed myotubes, we observed that IGF-I pathway, kinases
p70 S6, 4E-BP1, and ERK1/2 were activated. Furthermore,
AZA treatment increased MyHC protein content in stim-
ulated neo myotubes. Our work demonstrates that DNA
demethylation could plays an important role in promoting
the late phase of myogenesis, activating endocellular
pathways involved in protein increment and stimulating the
hypertrophic process.
Keywords Muscle differentiation  DNA methylation 
5-Azacytidine  Hypertrophic process  C2C12
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Introduction
Skeletal muscle regeneration and hypertrophy are impor-
tant adaptive responses to both disease and physical
activity [1]. Muscle repair is controlled by satellite cells
(SC), representing skeletal muscle stem cells [2]. In
response to injury, quiescent SC start to proliferate gen-
erating myogenic precursor cells (myoblasts). Myoblasts
withdraw from the cell cycle and form myotubes [3].
This process is principally governed by muscle regula-
tory factors (MRFs), including MyoD and Myf6 [4, 5].
MRFs regulate the cellular cycle progression, in particular
Myf6 cooperates with p21, a cell cycle regulator protein, to
promote muscle specific protein synthesis [6] such as
Myosin Heavy Chain (MyHC). Instead, the end of myo-
genesis [7] is lead by Myostatin (Mnst). Mstn, a member of
the transforming growth factor-b superfamily, is an
important negative regulator of skeletal muscle develop-
ment. Naturally, Mnst occurring mutations, as well as
experimental knockout of the Mstn gene, lead to hyper-
muscular phenotype [8]. In vitro model of skeletal muscle
cells, Mstn is predominantly localized in the nuclei of
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differentiated, polynucleated myotubes and down regulates
the muscle genes expression [9].
Muscle hypertrophy is an increment of existing muscle
fibers size [10], associated with an enhanced protein
accumulation. Insulin growth factor I (IGF-I) are crucially
involved in hypertrophic process induced by Growth
Hormone (GH) treatment or exercise [11, 12]. In recent
years, Spangerburg and other investigators have tried to
understand the mechanisms by which IGF-I may mediate
changes in muscle mass during mechanical loading. [13–
15]. The data, obtained by these researchers, are in part
controversial [16–19]: inhibition of IGF-I activity does not
eliminate increased muscle mass through mechanical load,
but driving IGF-I enhances the effects of load. Although a
controversial point of view, there is no doubt that IGF-I
could play a central role in muscle hypertrophy and
adaptation. In fact, IGF-I overexpression is sufficient to
induce muscle hypertrophy, modulating the entire circuit
necessary to guarantee it: an increase in protein synthesis, a
decrease in protein degradation, an activation and a fusion
of satellite cells [20–22].
Insulin growth factor I binding activates the IGF-I
receptor (IGF-I R), a receptor tyrosine kinase. The IGF-I R
subsequently recruits the insulin receptor substrate (IRS-1),
which results in the activation of two signaling pathways:
the mitogen-activated protein kinases (MAPK) pathway
and the phosphatidylinositol 3-kinase (PI-3 K) pathway
[23, 24].
The MAPK pathway is crucial in mitosis-competent
cells for cell proliferation and survival [25]. Extracellular
signal regulated kinases (ERK1 and ERK2), members of
the MAPK family, are involved in the regulation of
muscle mass. Myoblasts/myotubes have a unique bipha-
sic requirement for ERK activity [26]. ERK1/2 are crit-
ical for growth factor-induced cellular proliferation,
inhibitory to myoblastic differentiation. These kinases are
required for myotube fusion and appear critical to this
last process [27]. Moreover, in adult skeletal muscle,
high-intensity exercises have been shown to activate the
MAPK–ERK pathway and in vivo studies showed that
MAPK-dependent pathways affect both fiber size and
fiber type [28].
The PI-3 K pathway is the predominant pathway that
stimulates muscle protein synthesis and is believed to be
required for a normal hypertrophic response. PI-3 K direct
target is AKT [10, 24]. Under normal conditions, AKT
activation results in the formation of a signaling complex
termed TORC1, an important component of which is
mTOR [29]. Activation of mTOR leads to phosphorylation
of ribosomal protein S6 Kinase (p70 S6 K). p70 S6 K
phosphorylates an important ribosomal subunit that is
necessary for muscle protein translation, and deletion of
p70 S6 K in muscle results in smaller muscle fibers [30].
Furthermore, mTOR directly phosphorylates the eukaryotic
initiation factor 4E (4E-BP1). Once phosphorylated, 4E-
BP1 releases its inhibitory effect on the translation initia-
tion factor elF4E, which impairs inhibition of translation
initiation by coupling with the end CAP of mRNA [30, 32].
Recently, discoveries in the field of skeletal muscle
biology have made an effort to understand how epigenetic
modifications affect the myogenic lineage acquisition [33].
The observation that treatment with a methyltransferase
inhibitor, 5-azacytidine (AZA), converts C3H10T1/2
embryonic fibroblasts into muscle cells providing the first
relationship between DNA methylation and myogenesis
[34]. This correlation is further underscored by the finding
that promoters of MRFs, MyoD and Myogenin, are
demethylated during muscle cell differentiation [35, 36].
However, the specific impact of DNA demethylation on
late phase of differentiation and on muscle mass regulation
is not completely understood.
In our study, we used AZA to induce DNA demethyl-
ation during differentiation stages of C2C12 cell line, an
established model of satellite cell growth and differentia-
tion [37, 38]. Our data show that DNA demethylation could
stimulate myoblasts differentiation and promote hypertro-
phic process, through the activation of IGF-I pathway.
Materials and methods
Materials
Anti calnexin (H-70), anti MyoD (C-20), anti Myf6 (C-19),
anti Myostatin (GDF-8: N-19), anti MyHC (H-300), anti
p21 (C-19), anti IGF-I receptor-b (C-20), anti phosho p70
S6-kinase (Thr421/Ser 424), anti p70 S6-Kinase (C-18),
anti 4E-BP1 (R-113), anti eIF-4E (P-2), anti p-ERK1/2
(E-4), anti-ERK1 (K-23), and anti ERK2 (C-14) primary
antibodies and peroxidase or rhodamine-conjugated sec-
ondary antibodies were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). All other reagents
were purchased from Sigma Chem. Co. (St. Louis, MO,
USA). Mouse C2C12 myoblastic cells were purchased
from European Collection of Animal Cell Cultures
(ECACC).
Experimental protocol
C2C12 myoblasts were cultured at 37 C in humidified
5 % CO2 atmosphere in growth medium (GM), containing
DMEM (Dulbecco Modified Eagle Medium) supplemented
with 20 % (v/v) FBS (fetal bovine serum), 1 % penicillin–
streptomycin, and 1 % L-glutamine. Differentiation process
is initiated upon reaching subconfluence by switching
C2C12 myoblasts in differentiation medium (DM),
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containing DMEM supplemented with 1 % horse serum,
antibiotics, and 1 % L-glutamine [38]. While, C2C12 cells,
maintained in GM, spontaneously fuse in neo myotubes as
a result of the achievement of myoblasts confluence [39].
To study DNA demethylation action on differentiation
process, cells, seeded at 6 9 102 cells/cm2, were grown
until 80 % of confluence and then were maintained in GM
or DM containing 5 lM AZA (GMAZA and DMAZA).
5 lM AZA represents the optimal concentration to stimu-
late cells without cytotoxic effects [34, 40]. This evidence
was, furthermore, validated by our dose response experi-
ments (data not shown). Control cells were maintained in
GM or DM. Medium, with or without AZA, was changed
every 24 h. Cells were analyzed during intermediate (48 h)
and late (72 and 96 h) differentiation phases.
To investigate DNA demethylation effects on hyper-
trophic process, we used C2C12 cells after 72 h from dif-
ferentiation induction in DM: in our model, most of the
myotubes were completely formed in this phase. Neo
formed myotubes were treated with 5 lM AZA for 24 h
(AZAMT). Unstimulated cells (DMMT) were used as
control.
Growth curve and cell vitality test
C2C12 myoblasts were plated in 35 mm2 culture dishes
and grown in presence of GMAZA or DM. Control cells
were cultured in GM. Experiment continued until the
control cells have reached subconfluence [41]. Every day,
the cells were trypsinized and stained with trypan blue.
Both viable (non-stained) and non-viable (blue) cells were
counted using a hemacytometer. The total cell count
average values for each single day were used to plot a
growth curve for treated and controlled myoblasts. Cell
vitality was calculated by dividing the non-stained viable
cell count by the total cell count.
Global DNA methylation assay
The total genomic DNA was extracted from the cells
(treated with GM, DM, GMAZA or DMAZA) using the
Qiagen DNA Mini Kit (Qiagen Sciences, Maryland, MD)
following the manufacturer’s instructions. The integrity
and purity of DNA were spectrophotometrically examined
according to its A260/A280 absorption. The Global DNA
methylation levels were determined using MethylFlashTM
Methylated DNA Quantification Kit (Epigentek, NY, USA)
according to the manufacturer’s instruction. The methyl-
ated fraction of DNA is recognized by a 5-methyl-cytosine
(5-mC) antibody. With this colorimetric kit, the amount of
methylated DNA, which is proportional to the optical
density intensity, is quantified through an enzyme-linked
immunosorbent assay-like reaction (ELISA assay). The
reference DNA fragments containing 5-mC and 5-cytosine
are used respectively as the positive standard and negative
control to generate the standard curve. In particular, man-
ufacturer’s instruction indicates that the percentage of
5-mC in the total DNA is calculated using the following
formula:
% 5-mC ¼ Sample OD  Negative control OD
2  Slope  Input DNA amount  100 %
Slope of the standard curve is determined using linear
regression [42].
Immunoblotting analysis
C2C12 cells were homogenized in lysis buffer (50 mM
Tris/HCl, pH 7.4, 150 mM NaCl, 1 % Triton X-100, 1 mM
sodium orthovanadate (Na3VO4), 1 mM EDTA, 1 mM
PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mg/
ml pepstatin) and the obtained samples were sharked for
1 h at 4 C. Detergent-insoluble material was removed
from the cell suspension by centrifugation at 12,0009g for
30 min. Protein content was quantified using Bradford
method. Aliquots of 30 lg supernatant proteins were
resolved by SDS-PAGE and transferred to nitrocellulose
membrane (Protran Whatman Schleicher & Schuell), as
described [43]. The membranes were incubated with spe-
cific primary antibodies and then with HRP-conjugated
secondary antibodies. Equal protein loading per sample
was confirmed using antibody anti-calnexin. Immunore-
active bands were visualized by an enhanced chemilumi-
nescence method (Amersham Pharmacia Biotech,
Piscataway, NJ, USA). Densitometric analysis was per-
formed using the Scion Image Software (Scion Corpora-
tion, Frederick, MD, USA).
Immunofluorescence analysis and phase contrast
microscopy
Cells were fixed in 4 % paraformaldehyde, and indirect
immunofluorescence analysis was performed as described
[43]. Cells were observed using fluorescence Leica DM
IRE2 microscopy and Nikon Eclipse 50I microscopy. The
images of myotubes were captured using respectively IM50
software and Nis-Elements D 4.00 software (Leica Mi-
crosystems, Switzerland and Nikon Instruments Europe
BV, Netherlands). To verify that cells number in all con-
ditions was superimposable, nuclei were revealed with
DAPI staining. For myotube diameter and length dimen-
sions, the average measurement was generated from
approximately 150 myotubes. Ten fields were randomly
chosen and all MyHC-positive multinucleated cells (at
least 3 nuclei) in each field were measured. In detail, an
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average diameter per myotube was calculated as the mean
of three measurements taken along the length of the
myotube. As proposed by Menconi et al. [44], the mea-
surements were conducted in a ‘‘blinded’’ fashion on coded
pictures with the investigator being unaware of the group
from which the cultures originated. The experiments were
repeated three times. Live C2C12 cells were examined and
images acquired by phase contrast microscopy using the
same microscope and digital system described above.
Statistical analysis
Data are converted to fold change (FC) relative to the
control and presented as the mean ± SD. Statistical sig-
nificances differences between treatments were analyzed
using one-way ANOVA and Bonferroni post test or t-tests.
Results were considered significant when p B 0.05.
Results
In our differentiation model, early myotubes appeared 48 h
after differentiation induction (intermediate phase), and
myotubes formation was completed after 72–96 h (late
phase). We analyzed DNA demethylation effects, during
these stages, adding AZA both in GM and DM cultured
cells (GMAZA–DMAZA) at the beginning of the differ-
entiation process. In the first case (GMAZA), we would
delineate the possible ability of DNA demethylation to
accelerate myoblast spontaneous differentiation due to
cell–cell contact; and in the second (DMAZA), we would
determinate the probable role of DNA hypomethylation to
improve myogenesis process (Fig. 1).
First, proliferation and cell vitality assays were per-
formed in proliferative myoblasts to verify that 5 lM AZA
did not have toxic effect (Fig. 2a, b). The cell growth
curves showed that AZA and DM induced a significant
reduction in the cell growth rate in relation to the untreated
control (Fig. 2a). It is important to emphasize that AZA
action did not show a cytotoxic effect in C2C12 cells, as
revealed cell vitality assay (Fig. 2b). Moreover, in our
previous work, we in detail analyzed AZA effect on
myoblasts cell cycle progression: we demonstrated that this
DNA methylation inhibitor enhances myogenesis induction
modulating expression of checkpoint genes involved in cell
cycle progression and arrest, but no genes involved in
apoptosis phenomena. In fact, GMAZA cells showed a p53
protein content comparable to that of GM cells [45].
Also, to determine whether AZA produces changes in the
methylation patterns, we also studied the global DNA
methylation by specifically measuring levels of 5-mC in an
ELISA-like microplate-based format. As shown in Fig. 2c,
we did not observe significant DNA methylation status
changes in cells maintained in GM. In contrast, GMAZA
and DMAZA cells were characterized by dramatic global
DNA methylation reduction (At 48 h FC: 0.44 ± 0.07
GMAZA vs. GM, at 72 h FC: 0.35 ± 0.08 GMAZA vs.
GM, at 96 h FC: 0.33 ± 0.13 GMAZA vs. GM; at 48 h FC:
0.31 ± 0.16 DMAZA vs. GM, at 72 h FC: 0.17 ± 0.03
DMAZA vs. GM, at 96 h FC: 0.38 ± 0.003 DMAZA vs.
GM; F = 34.35, p B 0.00001 anova test followed by
Bonferroni post hoc test). In according to the previous data
[33, 40], we noticed a significant DNA hypomethylation
status in DM condition (at 48 h FC: 0.42 ± 0.09 DM vs.
GM, at 72 h FC: 0.59 ± 0.14 DM vs. GM, at 96 h FC:
0.52 ± 0.05 DM vs. GM; F = 34.35, p B 0.00001 anova
test followed by Bonferroni post hoc test). In detail, DNA
methylation status is similar in DM and GMAZA, sug-
gesting that AZA could improve differentiation process
regulating epigenetic mechanisms in analogous manner to
DM. Furthermore, exposure to DM and AZA resulted in the
most significant DNA methylation decreases, indicated that
AZA could strengthen muscle differentiation induced by
DM. Immunostaining of C2C12 cells with MyHC antibody
at 48 h supports the DNA global methylation result: there
was an evident increment in the number of MyHC-positive
cells in AZA treated than untreated cells (Fig. 2d). These
data confirm DNA demethylation action of AZA and indi-
cating that epigenetics regulation is a crucial aspect of
skeletal muscle differentiation.
For the success of the myogenesis program, sequential
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Fig. 1 Up schematic illustration of skeletal muscle differentiation.
Down simplified design of experimental procedures
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[3, 4]. In detail, MyoD reaches the highest expression in
early phase and represents a marker for this stage [5, 33].
Instead, Myf6 and skeletal protein MyHC, being expressed
during intermediate and late stages of differentiation, are
used as markers of these phases [33]. To characterize AZA
action on differentiation progression, we performed a
detailed temporal study of MyoD, Myf6, and MyHC pro-
tein synthesis (Fig. 3a).
Western blot studies showed that MyoD levels were
improved (Fig. 3b, FC: 1.22 ± 0.01 DM vs. GM) only in
DM cells during intermediate differentiation phase (48 h),
according to the previous data [3, 46]. At 48 h, unchanged
MyoD expression, observed in AZA treated cells, is maybe
due to AZA ability to promote MyoD synthesis. Probably
in AZA treated cells, MyoD peak synthesis occurred in the
hours before and MyoD protein content is returned to
baseline levels at 48 h. In fact, at 72 and 96 h, no signifi-
cant differences in MyoD content was established between
AZA treated and control cells.
As shown in Fig. 3c, at 48 h AZA considerably raise
Myf6 protein content and in DMAZA cells this effect was
detectable until the late stage (At 48 h FC: 1.66 ± 0.03
DMAZA vs. GM, at 72 h FC: 3.16 ± 0.08 DMAZA vs.
GM, at 96 h FC: 2.89 ± 0.09 DMAZA vs. GM;
F = 19.41, p B 0.00001 anova test followed by Bonferroni
post hoc test). Finally, we investigated MyHC protein
profile (Fig. 3d). At 48 h, both in GMAZA and DMAZA
MyHC content was already higher compared with control
(Fig. 3d, FC: 1.60 ± 0.03 GMAZA vs. GM, FC:
3.28 ± 0.03 DMAZA vs. GM, F = 94.05, p B 0.00001
anova test followed by Bonferroni post hoc test). In
GMAZA, extent of MyHC increase was less than in
DMAZA but was prolonged in time (at 72 h FC:
1.49 ± 0.12 GMAZA vs. GM, at 96 h FC: 2.01 ± 0.11
GMAZA vs. GM; F = 94.05, p B 0.00001 anova test
followed by Bonferroni post hoc test). As expected, in DM
condition MyHC amount increased only at 72 h (Fig. 3d
FC: 2.56 ± 0.17 DM vs. GM).
These results suggest that AZA has a positive role in
MyHC expression and, in association with DM, this
effectiveness AZA action is accelerated.
To verify the importance of DNA demethylation during
differentiation, we performed morphological analysis,
immunostaining C2C12 cells with MyHC antibody.
At 48 h (Fig. 4a) in GM condition, MyHC positive cells

































































Fig. 2 AZA effects on
myoblasts proliferation and on
global DNA methylation status.
a Growth curve trends were
obtain growing myoblasts until
40 % confluence in GM and
then were switched in GMAZA
or in DM. The experiment
continued until the cells reached
subconfluence. GMAZA and
DM negative influence C2C12
proliferative potential.
b Myotoxicity of AZA in vitro:
AZA did not induce cell death.
c Evaluation of AZA
demethylation action on global
DNA methylation status. Global
DNA methylation levels were
evaluated by an ELISA assay
specific for 5-mC.
d Immunofluorescence MyHC
analysis at 48 h in GM,
GMAZA, DM, and DMAZA
conditions. MyHC positive cells
are labeled in red. DAPI and
merge images are reported
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GMAZA cells were more elongated, assumed a bipolar
morphology and started to orient themselves in the same
direction. In DM cells, these processes were more
advanced and some groups of cells started to fuse. In
DMAZA, this aggregation state was more evident and
numerous myotubes were formed. At 72 h, GM cells fused
into clusters, while in DMAZA condition organized myo-
tubes were observed. GMAZA and DM cells were in an
intermediate condition and showed morphology very sim-
ilar to each other (Fig. 4b). At 96 h (Fig. 4c), already in
GM condition, neo formed myotubes were observed.
GMAZA and DM cells had similar morphology, suggesting
that AZA action on C2C12 myoblasts is superimposable to
DM effect. DMAZA myotubes appeared hypertrophic and
these morphological features suggest that DNA hypome-
thylation could improve myotube formation efficiency.



































proteins are shown. MyoD (b),
Myf6 (c), and MyHC
(d) proteins expression was
detected by western blot
analysis after 48, 72, and 96 h
of differentiation induction.
C2C12 myoblasts cultured in
four different conditions (GM,
GMAZA, DM, DMAZA). Data,
obtained from three independent
experiments, are expressed as
fold changes (FC) relative to
GM condition. The average,
expressed as fold changes (FC)
relative to control, are
graphically represented. Data
were obtained from three
independent experiments.
Comparisons were performed
using one-way analysis of
variance (ANOVA) followed by
Bonferroni post hoc tests
(****P \ 0.00001)
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To support AZA involvement in muscle hypertrophy,
myotubes dimensions were measured. During all phases,
GMAZA and DMAZA myotubes showed a significant
increase in diameter and length compared to GM (Fig. 4, at
48 h diameter FC: 1.33 ± 0.58 GMAZA vs. GM, 2.32 ± 0.79
DMAZA vs. GM; at 48 h length FC: 1.90 ± 0.52 GMAZA
vs. GM, 2.60 ± 0.56 DMAZA vs. GM; at 72 h diameter FC:
1.53 ± 0.61 GMAZA vs. GM, 2.10 ± 0.47 DMAZA vs.
GM; at 72 h length FC: 1.40 ± 0.34 GMAZA vs. GM,
1.80 ± 0.52 DMAZA vs. GM; at 96 h diameter FC:
1.93 ± 0.75 GMAZA vs. GM, 2.03 ± 0.54 DMAZA vs.
GM; at 96 h length FC: 1.21 ± 0.27 GMAZA vs. GM,
1.34 ± 0.28 DMAZA vs. GM; for length F = 17.61,
p B 0.00001, for diameter F = 27.24, p B 0.00001 anova
test followed by Bonferroni post hoc test). Moreover, at 96 h,
there was still a significant difference between the diameter of
GMAZA myotubes and those kept in GM, which instead
disappears between the diameters of myotubes grown in DM
compared to GM, suggesting a hypertrophic effect of AZA.
Furthermore, we studied myotubes nuclear disposition
during late phase of myogenic differentiation (96 h). As
shown in Fig. 5, immunofluorescence analysis, using
antibodies against p21 and Myostatin, revealed that AZA
treated myotubes were characterized by a particular
arrangement of nuclei to form a ring. This nuclear orga-
nization represents a morphological marker of in vitro
muscle hypertrophy [47].
To confirm DNA demethylation influence in hypertrophic
process, we investigated AZA action on signaling pathway
involved in hypertrophy using C2C12 neo formed myotubes.
C2C12 neo formed myotubes, after 72 h of differentiation,
were treated with AZA for 24 h (AZAMT). Control cells were
maintained in DM medium (DMMT), Fig. 6a. As expected,
5-mC ELISA assay revealed a significant DNA hypomethy-
lation in AZAMT compared with unstimulated neo myotubes
(Fig. 6b, FC: 0.23 ± 0.02 AZAMT vs. DMMT, p B 0.01).
Insulin growth factor I represents a crucial factor in
skeletal muscle mass regulation and its activity predomi-
nantly requires the binding to IGF-I R [10, 24]. IGF-I R is
synthesized as a single polypeptide chain (Pro IGF-I R) that
is processed to mature receptor. The previous studies suggest
that IGF-I promotes muscle hypertrophy by p70 S6 K and
4E-BP1 activation. 4E-BP1 phosphorylation frees eIF-4E
promoting the protein synthesis beginning [24, 29, 31].
Pro IGF-I R protein level was higher in AZA treated
myotubes (AZAMT) than in control (DMMT) (Fig. 6d FC:
1.66 ± 0.03 AZAMT vs. DMMT, p B 0.02), while AZA
action on IGF-1 R expression was less prominent (Fig. 6d,
FC: 1.32 ± 0.04 AZAMT vs. DMMT, p B 0.05). Proba-
bly, deep changes in IGF-I R synthesis could be observed
after 96 h of myotubes differentiation.
As expected, AZA treated myotubes were associated
with enhanced activation of p70 S6 K, as shown by the





analysis of C2C12 cells,
differentiated for 48 (a), 72 (b),
and 96 (c) hours in GM,
GMAZA, DM, and DMAZA
conditions. MyHC positive cells
are labeled in red.
Representative DAPI images
are reported. The length (d) and
diameter (e) of MyHC positive
myotubes were measured. The
average, expressed as fold
changes (FC) relative to GM
control, are graphically




analysis of variance (ANOVA)
followed by Bonferroni post hoc
tests (****P \ 0.00001)
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phosphorylated protein (Fig. 6e, p70 S6 K/p70 S6 K FC:
1.36 ± 0.03 AZAMT vs. DMMT, p B 0.04).
4E-BP1 has three electrophoretic forms, designated a, b,
and c in order of increasing mobility, inversely related to
their phosphorylation state [31]. In our myotubes, 4E-BP1
was present only in the a and b forms. AZA stimuli
decreased the amount of a form and increased b form
content, as evidenced by the two isoforms ratio (4E-BP1b/
4E-BP1a) (Fig. 6f, FC: 1.50 ± 0.06 AZAMT vs. DMMT,
p B 0.05). Moreover, we observed an eIF-4E protein level
increment in AZA neo formed myotubes (Fig. 6g, FC:
1.31 ± 0.03 AZAMT vs. DMMT, p B 0.04).
Insulin growth factor I signaling pathway actives the
MAPK pathway. ERK1 and ERK2, principal members of
MAPK cascade, play a key role in hypertrophic process [10,
26]. We studied ERK1 and ERK2 activation: AZA treatment
increased the ratio between phosphorylated versus un-phos-
phorylated ERK1 and ERK2 (Fig. 6h, i, pERK1/ERK1 FC:
1.74 ± 0.02 AZAMT vs. DMMT, p B 0.04, Fig. 5i, pERK2/
ERK2 FC: 1.55 ± 0.05 AZAMT vs. DMMT, p B 0.05).
Furthermore, Fig. 6j showed an increased tendency in
MyHC protein amount in AZA treated myotubes, sug-
gesting an activation of the protein translational machinery
(FC: 1.21 ± 0.02 AZAMT vs. DMMT, p B 0.00001) and
the signaling cascades involved in hypertrophic mecha-
nisms. Finally, to confirm this deduction bright field
microscopy images (Fig. 6k) indicated that in AZAMT cell
the hypertrophic process was more marked.
Discussion
Several investigators [34, 40, 45, 48], including us, have
shown that DNA demethylation promote MRFs expression
and skeletal muscle differentiation induction. In the present
study we explored AZA treatment effects during myoblasts
differentiation. We, also, investigated AZA action on neo
formed myotubes to evaluate its possible impact on
hypertrophic process.
Our results demonstrated that during intermediate and
late differentiation phase AZA strengthens and promotes
Myf6 and MyHC expression compared to untreated cells.
The morphological analysis confirmed that myoblasts
aggregation, orientation, and fusion come earlier in AZA
treated cells. Also, AZA stimuli increases myotubes length
and diameter. Therefore, AZA demethylating action
shortens the differentiation process, maintaining the
ordered and sequential expression of the muscle-specific
gene program.
The present in vitro data lead to a number of
considerations.
First, our findings point to the interactions between AZA
and DM on muscle cells differentiation. Specifically, the
AZA–DM association has a synergistic action in enhancing
myogenic process and giving hypertrophic stimuli. In fact,
only in DMAZA condition p21 and Mnst-positive myotu-
bes showed the nuclear distribution shaped a ring, typical
of muscle hypertrophy in vitro [47].
Second, we investigated AZA action on IGF-I signaling
pathway involved in skeletal muscle hypertrophy. We
observed that AZA-induced DNA hypomethylation could
improve IGF-I R protein synthesis. This is supported by a
recent study demonstrating that IGF-I R synthesis is reg-
ulated by DNA methylation [49]. We evaluated the AZA
action on p70 S6 K, 4E-BP1, and eIF-4E proteins, essential
regulators of protein synthesis. We demonstrated that AZA
activates these proteins that, at the end, lead to a raise of
MyHC protein content, reflecting the increased overall
Fig. 5 Hypertrophic myotubes morphological study. p21 (a) and Mnst (b) immufluorescence analysis of C2C12 cells cultured in GM, GMAZA,
DM, and DMAZA conditions after 96 h of differentiation. p21 and Mnst positive cells are labeled in red
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protein synthesis. These results suggest the possible cor-
relation between epigenetic mechanisms and muscle pro-
tein accretion.
Importantly, our data may have a potential impact
in vivo regulation of protein metabolism. In fact, IGF-I is a
fundamental mediator of the hormonal and metabolic
action of Growth Hormone. GH is secreted in many
physiological and stress-related conditions [50]. Our results
suggest that AZA might be synergistic to GH in fostering
the IGF-I mediated actions [51]. We may speculate an
hypothetical clinical use of demethylating agents in con-
ditions of muscle mass impairment/hypotrophy. A syner-
gistic effect of 5-azacytidine and hGH-V (human placental
growth hormone) was previously established [52].
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Fig. 6 Insulin growth factor I signaling pathway study. a Simplified
scheme of experimental protocol: C2C12 cells, after 72 h of
differentiation induction, were treated for 24 h with (AZAMT) or
without (DMMT) AZA. b Evaluation of AZA demethylation action
on global DNA methylation status. Global DNA methylation levels
were evaluated by an ELISA assay specific for 5-mC. c Representative
immunoblots of analyzed proteins are shown: western blot analysis of
Pro IGF-I R and IGF-I R (d), pp70 S6 K/p70 S6 K ratio (e), 4E-
BP1b/4E-BP1a ratio (f), eiF-4E (g), pERK1/ERK1 ratio (h), pERK2/
ERK2 ratio (i), and MyHC (j). Images obtained by bright field
microscopy at the end of experiment (k). Data, obtained from three
independent experiments, are expressed as mean ± SD fold changes
(FC) relative to DMMT. Significance: *p \ 0.05, **p \ 0.04,
***p \ 0.03, ****p \ 0.02, op \ 0.00001 versus DMMT condition
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Third, the demonstration that AZA-induced DNA
demethylation accelerates the skeletal muscle differentia-
tion might constitute a new model to study the patho-
physiology of several genetic muscle diseases. Recent
studies have evidenced that DNA hypermethylation is
correlated with genetic skeletal muscle diseases, like
Duchenne muscular and myotonic dystrophy [53, 54].
Hupkes et al. [40] have reported that AZA induced-DNA
demethylation enhances skeletal muscle function, in par-
ticular AZA promotes the acquisition of spontaneous
contractility in C2C12 cell model. Accordingly and con-
cordant with these data, our results demonstrate that DNA
hypomethylation could improve skeletal muscle differen-
tiation. Taken together, these data confirm the idea that the
DNA methylation could represents the epigenetic key point
regulating skeletal muscle differentiation and that drugs or
other stimuli, which promote DNA demethylation, could
modulate muscle differentiation.
Fourth, our observation that AZA and DM association
induces hypertrophic response implies a link with the most
important physiological stimulus leading to muscle hyper-
trophy: exercise training. Very recently, Barre`s et al. [55]
demonstrated that acute exercise leads to transient changes in
DNA methylation in key genes of skeletal muscle metabo-
lism. In addition, our previous study that showed a significant
association between elite´ athletes phenotype (enhanced
muscle mass) and polymorphic variants involved in DNA
methylation [48]. Considering all together, the above con-
siderations suggest an important regulatory role of DNA
methylation on muscle mass accretion.
In conclusion, we demonstrated that DNA demethyla-
tion enhances myoblasts differentiation and hypertrophy
during the late phase of myogenesis and that this effect is
mediated via activation of the IGF-I receptor and post-
receptor phosphorylation cascade. The present results
constitute a proof of principle of potential effects of
5-azacytidine on muscle protein accretion.
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